Last 21 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -20.70 | — | — | — | — | — | 9.16 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 14.06 | 4.48 | 4.58 | 4.94 | 6.62 | 10.15 | 3.60 | 36.64 | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | -55.8% | +27.2% | -86.5% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 5.05 | 2.18 | 1.62 | 1.45 | 1.70 | 2.36 | 2.43 | 3.91 | 4.82 | 3.67 | 2.71 | 2.10 | 3.20 | 4.76 | 3.92 | 2.78 | 2.23 | 3.71 | 4.94 | 4.52 | — |
| — | -7.4% | -33.5% | -62.9% | -64.8% | -35.8% | -10.2% | +86.3% | +50.6% | -22.8% | -30.9% | -24.5% | +43.6% | +28.2% | -20.7% | -38.4% | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | 7.65 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | 6.43 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 89.1% | 88.7% | 88.7% | 88.9% | 90.6% | 89.8% | 98.3% | 91.4% | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | -1.2% | -9.7% | -2.7% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | -80.8% | -51.1% | -60.9% | -103.1% | -133.5% | -223.7% | 31.6% | -1401.5% | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | +77.1% | -292.8% | +92.6% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | -67.8% | -39.6% | -49.6% | -89.4% | -117.0% | -225.0% | 39.5% | -53.8% | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | +82.4% | -225.5% | -66.2% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -22.7% | -4.8% | -4.3% | -6.4% | -7.3% | -12.4% | 8.6% | -1.5% | -19.4% | -14.8% | -11.3% | -12.6% | -13.4% | -11.5% | -10.0% | -11.2% | -10.3% | -7.6% | -6.3% | -6.1% | -27.8% |
| — | +61.6% | -150.4% | -341.6% | +62.2% | +16.1% | +175.9% | +88.4% | -44.7% | -28.3% | -12.8% | -12.4% | -30.6% | -52.2% | -58.8% | -84.7% | +63.1% | — | — | — | — | |
| ROA | -19.7% | -4.2% | -3.8% | -5.8% | -6.4% | -11.1% | 7.4% | -1.2% | -17.8% | -13.8% | -10.7% | -11.8% | -12.6% | -11.0% | -9.6% | -10.9% | -10.0% | -7.4% | -6.2% | -6.0% | -14.7% |
| — | +62.5% | -151.6% | -374.9% | +63.7% | +19.5% | +169.3% | +89.8% | -40.9% | -25.7% | -10.9% | -8.9% | -26.7% | -48.5% | -55.1% | -81.8% | +32.3% | +90.2% | — | — | — | |
| ROIC | -30.5% | -6.3% | -4.3% | -6.0% | -7.4% | -19.0% | 21.9% | -183.2% | -70.1% | -33.7% | -20.0% | -15.1% | -13.8% | -13.1% | -24.2% | — | — | — | -1009.5% | -443.4% | — |
| — | +67.0% | -119.8% | +96.7% | +89.4% | +43.6% | +209.9% | -1113.1% | -409.0% | -157.8% | +17.5% | — | — | — | +97.6% | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 | Q2 '21 | Q1 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| — | +22.3% | +36.3% | +952.7% | +501.5% | +339.8% | +256.9% | -57.3% | -57.6% | -51.9% | -50.9% | -45.7% | +262.2% | +212.8% | +199.7% | +166.2% | -71.0% | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | 0.09 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 8.02 | 8.02 | 8.68 | 9.65 | 10.62 | 7.66 | 14.62 | 4.09 | 10.93 | 12.72 | 16.89 | 18.35 | 14.11 | 20.94 | 20.83 | 31.45 | 32.70 | 33.43 | 50.17 | 67.79 | 51.78 |
| — | +4.7% | -40.6% | +136.1% | -2.8% | -39.8% | -13.4% | -77.7% | -22.6% | -39.3% | -18.9% | -41.7% | -56.9% | -37.4% | -58.5% | -53.6% | -36.8% | +48.0% | — | — | — | |
| Quick Ratio | 7.91 | 7.91 | 8.55 | 9.53 | 10.55 | 7.61 | 14.55 | 4.09 | 10.93 | 12.72 | 16.89 | 18.35 | 14.11 | 20.94 | 20.83 | 31.45 | 32.70 | 33.43 | 50.17 | 67.79 | 51.78 |
| — | +3.9% | -41.2% | +133.0% | -3.5% | -40.2% | -13.8% | -77.7% | -22.6% | -39.3% | -18.9% | -41.7% | -56.9% | -37.4% | -58.5% | -53.6% | -36.8% | +48.0% | — | — | — | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -3205.67 | -2209.43 | -2299.14 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 21 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying DAWN stock.
Day One Biopharmaceuticals, Inc.'s current P/E is -20.7x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Day One Biopharmaceuticals, Inc.'s current operating margin is -80.8%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Day One Biopharmaceuticals, Inc.'s business trajectory between earnings reports.